TOWARD FURTHER EXPANSION
THE 7TH WORLD CONGRESS

VII™ WORLD CONGRESS
INTERNATIONAL SOCIETY for DISEASES of the ESOPHAGUS
MONTREAL
SEPTEMBER 1-4, 1998

- CELEBRATING -
* 20 YEARS *
* OF THE ISDE *

ANDRE DURANCEAU, M.D.
7TH CONGRESS CHAIRMAN
PROFESSOR OF SURGERY
HOTEL DIEU DE MONTREAL
QUEBEC, CANADA

Montreal, the Province of Quebec and all of Canada are proud and honoured to have been selected as the host city of the 7th World Congress of the International Society for Diseases of the Esophagus in 1998. The meeting will take place during the week of August 31st to September 4th.

Our modern and dynamic city is very North American and yet it retains it's French origin and culture. It's international character will create an ideal setting for our Society to meet in six years from now.

The high quality of our Convention Center facilities, located right in the heart of Montreal as well as the professional and technical support should ensure the success of our congress. The strong presence of our two major universities, Université de Montréal and McGill University should guaranty the highest scientific level for our meeting.

Our aim is to provide the best organized platform for our exchange. Our city's aim is to offer the most pleasant surrounding to our visitors for such an occasion.

On behalf of Montreal, Quebec and Canada, I invite you to be with us for our International Congress in 1998.

A tres bientot.
II. RECENT ORGANIZATIONAL DEVELOPMENTS

The 15th of the Executive Committee Meeting was held on May 26, 1996 at Melia Madrid Hotel, Madrid, Spain. The following reports were given.

1) Membership Committee;
   As of May 1, 1996 there were 705 members, an increase by 3 compared to 1995, 702. Among 30 new members, there are 5 gastroenterologists. Thirty-four members withdrew in 1995 including 16 by notification, 17 through not paying dues and one due to death. The rate of payment of annual dues was 84%. Professor Skinner proposed the idea of the distribution of the journal should be halted for those not paying dues for the previous year.

2) Scholarship Committee;
   As to the scholarship candidates for 1996, it was reported that 4 research scholars and one visiting scholar were selected by mail evaluation among the committee members. As of 1996, 58 members have received the scholarship approximately half of whom were from countries having financial problems.

3) Newsletter Committee;
   Dr. Watanabe, the chairman of the Committee reported that the No. 19 issue had been published and that the affairs were going smoothly.

4) Journal Committee;
   Professor Siewert, Editor-in-Chief reported on the production process. Volume 9, No: 2 issue (1996 April issue) recently came out on time. Listing in medical indexes is strongly needed.

5) Video-Library Committee;
   Dr. Rosati reported the process of forming the Video-Library. Glaxo indicated their willingness to cover costs incurred in Milan by editing duplicating and mailing cassettes that are sent to Milan. They will not be responsible for the creation of videos of procedures or those made at congresses.

6) The 7th World Congress;
   Congress Chairman Professor Duranceau reported on preparations showing the titles of main sessions and the time table.

7) The 8th World Congress;
   Proxy of the Congress Chairman Professor Pinotti, Dr. Cecconello reported on the preparation status.

1996 Scholarship Recipients

KEUL ABE
Dept. of Surgery II
Tohoku University, School of Medicine
Sendai, JAPAN
(NATIONAL INSTITUTE OF HEALTH, NATIONAL CANCER INSTITUTE, USA)

LONG-QI CHEN
Dept. of Thoracic Surgery
Hebei Medical University
Shijiazhuang, P. R. CHINA
(HOTEL-DIEU DE MONTREAL, CANADA)

RANJIELOVIC, TOMISLA V
Dept. of Surgery
Institute for Digestive Diseases
Clinical Center of Sarajevo
Belgrade, YUGOSLAVIA
(TORANOMON HOSPITAL, JAPAN)
III. REGIONAL ACTIVITY

USA

F. Henry Ellis, Jr. M.D., Ph. D.
Clinical Professor of Surgery Emeritus
Chief Emeritus
Division of Cardiothoracic Surgery
Deaconess Hospital
Harvard Medical School

"During the spring of 1996, three important national thoracic surgical meetings were held in the United States, at which interesting esophageal papers were presented."

The Society for Thoracic Surgeons met in late January, and a group from the University of Michigan presented an interesting paper suggesting that Barrett's adenocarcinoma may represent a subset of tumors of the cardia. Using Sucrase Isomaltase (SI) analysis, they found that 7 of 21 tumors of the cardia without associated Barrett's mucosa (33%) were SI positive, suggesting that these tumors may represent Barrett's adenocarcinoma, and that there exists a subset of tumors of the cardia that are true Barrett's adenocarcinoma rather than gastric tumors. Dr. Ferguson from the University of Chicago confirmed findings previously published from the Mayo Clinic that prior forceful dilation of the esophagus for achalasia has no adverse effect on subsequent surgery, which in their case consists of esophagomyotomy and fundoplication. A prospective study of photodynamic therapy for esophageal malignancy was presented from Columbus, Ohio. Complications and procedure-related mortality were minimal, and the duration of palliation of dysphagia was equal to or better than that of most other treatment regimens. An interesting poster by Altorkis group from the New York Hospital found that acidic fibroblast growth factor (aFGF) was present in all 1 patients with high grade dysplasia and Barrett's esophagus, and in 90% of those with carcinoma, suggesting that aFGF may prove to be an important marker of invasive carcinoma in these cases.

The Annual Meeting of the American Association for Thoracic Surgery was held in San Diego, CA during the last week in April. A combined paper from Montréal, Quebec, and Milan entitled Cricopharyngeal Myotomy For Neurogenic Oropharyngeal Dysphagia described 40 patients with a variety of such disorders, thirty of whom were either asymptomatic or improved after operation. These findings are important, for they do not reflect everyone's experience with cricopharyngeal myotomy for patients whose cervical esophageal dysphagia is the result of the neurogenic factors. The Mayo Clinic reported in detail on their experience with reoperation after failed antireflux procedures involving 185 patients with an improvement rate approaching 90%. They stressed, as have others, that the type of repair should be tailored to the individual patient, but emphasized that esophageal preservation, rather than resection, will result in significant functional benefit, with low mortality and morbidity. The same group addressed the question of anemia associated with paraesophageal hiatus hernia, re-emphasizing the fact that repair of the hernia without associated procedures will successfully correct the anemia in most of these patients.

The Western Thoracic Surgical Association met in late June, and two important papers on esophageal cancer were presented. Dr. Ellis' group from the Deaconess Hospital and Harvard Medical School presented their experience with 454 patients with carcinoma of the esophagus and cardia, 408 (90%) of whom underwent resection with a 30-day mortality of 2.5%. These patients were divided into three separate time intervals of 8 years each. Significant findings were an increase in left thoracic and transhiatal approaches, with a decline in thoracoabdominal incisions. The percentage of RO resections increased, while that for R1 resections decreased with no change in R2 resections. There was a marked increase in the percentage of adenocarcinomas in Barrett's esophagus, and in Stage 0 and 1 tumors. The overall adjusted actuarial five-year survival rate was 4.7%, and was higher during the most recent time interval than the previous one (28.8% versus 29.3%). New staging criteria, based on modifications of Skinner's WNM criteria, were found to provide better prognostic stratification of patients by stage than is true of that currently used by the AJCC and the UICC. Dr. Akiyama of Tokyo presented his extraordinarily successful results with resection of esophageal cancer some of which had been previously reported.

(F. Henry Ellis, Jr., M.D. Ph. D.)
IV. ISDE SCHOLARSHIP

SCHOLARSHIP REPORT I.
Haruhiro Inoue, M.D.
First Department of Surgery
Tokyo Medical and Dental University

First of all I would like to thank the scholarship committee for giving me the opportunity to visit USC hospital (Department of Surgery, University of Southern California, Director and Professor Tom Ryan DeMeester). I spent three months from January to March 1995 at this university. As you know, Prof. DeMeester and his colleagues are worldwide renowned for their splendid dedication to the diagnosis and treatment of various kinds of esophageal diseases. During my stay in Los Angeles I observed a great deal of their activity concerning basic research and clinical work. Particularly, many reflux disease patients are referred and appropriately treated according to their original protocol. "Esophageal lab" is a special room, where they perform functional studies of the esophagus. I learned many things concerning esophageal motility, pH study and bile juice reflux. This room works every day of the week, and I spent most of my afternoons there, after observing the surgeries in the morning.

One of the most interesting points for me is that laparoscopic Nissen fundoplication has already been established and has become the gold standard of treatment for reflux disease, in which they can perform complete laparoscopic procedures relevant to open surgery.

It was also to my surprise that more than 90 percent of esophageal cancer patients in USC hospital are occupied by adenocarcinoma developed on Barret esophagus. This is quite different from the incidences in Japan where almost all cases are squamous cell carcinoma. As you know, advanced disease of either squamous cell carcinoma or adenocarcinoma has very poor prognosis. Thus early detection of this disease is important and appreciated. In order to detect early-stage squamous-cell carcinoma, spraying of iodine-dye solution is, of course, quite useful. But early detection of adenocarcinoma is relatively difficult. At present we have no effective vital staining technic for early-stage adenocarcinoma, and therefore multiple biopsies are effective to detect them.

During my stay in Los Angeles, two big disasters occurred in Japan. One was the subway carin attack by Aum Supreme and the other was the Kobe's earthquake. I could not believe myself when I first saw it on CNN news. I will never forget those scenes of my mother country on TV for the rest of my life.

In USC Hospital, Dr. Jeffrey H Peters (Assistant professor of Surgery) and Professor Cedric Bremner especially helped me in many ways. I would like to express my appreciation for his kindness once again. (Haruhiro Inoue, M.D.)

THE ISDE SCHOLARSHIP

Source of Funds:
The Japanese Research Foundation for the Multidisciplinary Treatment of Cancer.

Purpose:
To encourage the transfer of information concerning the diagnosis and treatment of esophageal diseases among specialists in various countries.

Eligibility:
1) Applicants must be ISDE members who have fully paid their dues for at least the previous year.
2) Applicants must submit an outline of the research they wish to undertake, and give their reason for choosing the proposed host institution. The host institution should preferably be one with experienced and qualified staff members who have contributed to the ISDE.
3) Applicants must provide evidence of acceptance at the proposed host institution.
4) Applicants must attach a letter of recommendation from the chief of his or her department.
5) Applicants must be on the staff of a university, teaching hospital, research laboratory or similar institution.

6) In principle, applicants for Research Scholarship must be under the age of 45, and must be able to work for a minimum of 3 months at the intended host institution.
7) Professors or chiefs of departments are eligible only for short-term grants (Visiting Scholarships).

Financial Support:
Stipends for Research Scholarships will be granted towards the cost of travel/cab fare, air fares and accommodations in the host country. No allowance will be given for dependents. In the case of Visiting Scholarships (item 7) above), only the cost of air fare and not of accommodation will be granted. This grant does not necessarily exclude the receipt by the grantee of other stipends to enable him or her to conduct the intended research.

Maximum Support per Award:
US $10,000

Total Amount of Support per Annum: Approximately US $70,000

Number of Awards: 6 - 7 per annum

Applications: (To P.5)
SCHOLARSHIP REPORT II.
Paul De Leyn, M.D.
University of Leuven
BELGIUM

It was a great pleasure for me to gain the support of the International Society of Diseases of the Esophagus to work for a six-month period in the Birmingham Heartlands Hospital (01/95 until 07/95). First of all, I would like to thank the staff, nurses and secretaries of the Thoracic Surgical Unit for their hospitality.

During these months, I have been working mainly with Miss Deidre Watson and Professor Hugh Matthews, both Consultant Thoracic Surgeons. As in Belgium most endoscopic work is performed by "endoscopists", Miss Watson took the time to familiarize me with rigid and flexible oesophagoscopy and stenting. This practice, together with the high quality of operative work and her very critical and sharp mind learned me a lot about curative and palliative treatment of oesophageal carcinoma. Correct diagnostic work-up, correct pre- and postoperative decisions are of paramount importance in this difficult field.

Professor Matthews is an eminent Thoracic Surgeon. His main interest is focusing on oesophageal diseases. His unit is a referring centre for oesophageal motility disorders and reflux disease and I have learned a lot about diagnosis and treatment of functional diseases of the oesophagus. Especially his oesophagus. Especially his oesophageal motility laboratory with research programme on histological changes in motility disorders and reflux disease have impressed me very much.

My main interest was the treatment of oesophageal carcinoma and the effect of induction chemotherapy. As we all know, carcinoma of the oesophagus remains difficult to treat, mainly due to the late diagnosis of the disease. There are scattered data in the literature that induction chemotherapy seems to increase the resectability and long-term survival of oesophageal carcinoma. In our institution in Leuven, patients with potential T4 or T4 disease receive induction therapy. In Professor Matthews unit, all suitable patients with oesophageal cancer (i.e. patients with assessable tumor, normal renal function, ... ) receive two pulses of chemotherapy. Two pulses of chemotherapy are given 21 days apart, followed by re-evaluation with CT scan and Barium swallow 21 days after the second pulse of chemotherapy. Following this, surgery was performed. Previous studies had shown that adding more courses to the chemotherapy regimen had no effect on the response rate. Also patients which were not surgical candidates (high operative risk, metastatic disease) were evaluated for chemotherapy.

(From P.4)

In 1997 Applications (one original and 10 copies attached photographs – not copies) should be received by the ISDE by December 31 1996, including proof of acceptance from the intended host institution(s). Notification of awards will be made by March 31, 1997 and the grantee should then finish his or her research by the end of March 31, 1998.

Limitations:

I was pleased to find that the toxicity was very acceptable. The toxicity consisted mainly of nausea and vomiting. No severe haematological problems or therapy related deaths were noted during this six-month period. The drug regimen was MIC (mitomycin, ifosfamide, cisplatin) or MCFu (mitomycin, cisplatin, 5-fluoracil). Barium swallow showed to be the best parameter to follow the response. The overall response was 62% for squamous cell carcinoma (22% complete and 39% partial response). The response rate for adenocarcinoma was lower (28-23%). At the moment, further promising studies are done to find if some histological features on preoperative biopsy can predict the response to chemotherapy. Such a finding would be a great importance since this would allow us to select patients which would definitely benefit from induction chemotherapy.

Professor Matthews has an unique technique in performing subtotal oesophagogastronomy. The anastomosis is almost always performed at the cervical level, since the incidence of reflux is much lower as compared with intrathoracic anastomosis. Much attention is paid to estabilish the patients immediately after the operation. When necessary, a miteatralectomy is inserted to facilitate aspiration of parietal. Patients have no nasogastric tube and they are allowed to start to drink small amounts of water 48 hours postoperatively.

Professor Matthews is an expert in all parts of general thoracic surgery and the ward rounds were always highly interesting for me. I very much enjoyed his critical remarks based on solid experience and with typical Britisch sense of humor and phlegm. I am sure that my stay at Birmingham Heartlands Hospital will change my ideas and techniques in thoracic surgery. Neoadjuvant therapy for carcinoma of the oesophagus seems to show encouraging results, with acceptable toxicity. It is obvious that further work needs to be done to evaluate the effect on survival.

Many people have helped me during this stay. I especially like to thank Mr. Collins, director of the Thoracic Surgical Unit, Mr. Marzouk, Consultant Thoracic Surgeon, Mr. Styn, Research Registrar, Mr Duffy, Senior Registrar and Jane Danion, Oesophageal Research Centre, Birmingham Heartlands Hospital.

Finally, I would like to thank the Head of my Departmet, Professor Dr. T. Lerut who is a very eminent oesophageal surgeon. He was the promoter of my basic fundamental research and make the contact with Professor Dr. Matthews. Again, I wish to thank the International Society for Diseases of the Esophagus for their support for my interest in oesophageal oncology.

(P. De Leyn, M.D.)
SCHOLARSHIP REPORT III.
Carmelo Loinaz, M.D.
Hospital "12 de Octubre"
Universidad Complutense de Madrid, Spain

I had the marvellous opportunity to spend a period of
time, from November 1995 to February 1996, at Cornell
University Medical Center-New York Hospital, thanks to the
95 ISDE Scholarship. This is the first hospital in New York City
and the second oldest in the United States, and was chartered
in 1711. Located on the upper East side of Manhattan, The
New York Hospital is affiliated with the Cornell University
Medical College together with the Hospital for Special
Surgery and the Memorial Sloan Kettering Cancer Center.
The faculty is world renowned for its contributions to
cardiac care, teaching and research.

It has been a wonderful experience to observe a lot of
operations performed by Prof. David B. Skinner and Dr.
Nasser K. A. Torki, both on benign and malignant esophageal
diseases, and have the chance to discuss the indications,
technical aspects and approach possibilities.

The standard technique for the surgical treatment of
esophageal carcinoma at The New York Hospital is "en bloc"
resection. This was developed by Dr. Skinner, after the first
report by A. Logan in 1963 (The surgical treatment of
carcinoma of the esophagus and cardia. J Thorac Cardiovasc
Surg 46:150). The first "en bloc" resection was performed in
1965, and the technique published in 1965 (En bloc resection
for neoplasm of the esophagus and cardia. J Thorac
Cardiovasc Surg 85:39). For tumors located at the upper and
middle third, or lower third within 10 cm of the aortic arch, a
right thoracotomy in the fifth intercostal space is used. When
the carcinoma is at the cardia or distal esophagus and
proximal margin of at least 10 cm is possible, a left sixth
intercostal thoracotomy incision is performed. In this case, a
diaphragmatic incision is done, avoiding the need of a
laparotomy or a thoracoabdominal incision. The esophagus is
resected "en bloc" with all the surrounding tissue, including
the mediastinal pleura. The stomach, the descending thoracic
duct, all existing lymph nodes and a pericardial patch.

The abdominal lymphadenectomy (hepatic, splenic and
celiac) is performed through the left thoracotomy in the
lower tumors or through a midline laparotomy. The lesser
curve curvature of the fundus to the fourth branch of the left
gastric artery, together with this artery and its lymph nodes
is resected with the esophageal specimen.

A third field lymph node dissection is now accomplished
through bilateral cervical incision, allowing removal of the
depth-lateral, jugular and recurrent nodes.

I observed as well some cases of gastroesophageal reflux
diseases treatment cases, with the Belsey-Mark IV procedure.
This is a technique with which they have a tremendous
experience and magnificent results.

During the time I have been in New York I have studied
and discussed profoundly the different procedures of
esophageal reconstruction. As a result of it, we are going to
publish the chapter "Pitfalls and complications of esophageal
interposition procedures" in the "issue of chest Surgery clinics
of North America on Pitfalls of Esophageal Surgery and their
prevention", edited by Dr. S. Fell and Dr. M. Bains. This work
will treat the different kinds of substitutes, i.e. stomach, colon
and pedicled or free jejunum, with their indications, pitfalls
and complications.

I want to thank the ISDE for the superb opportunity I had
to spend such a wonderful time in New York, and meet such
marvellous surgeons as Prof. Skinner, an internationally
renowned esophageal surgeon that does not need any
introduction, and Dr. Attorki, an experienced and skillful
cardiothoracic surgeon, actively working on esophageal
surgery but lung and cardiac surgery too. It has been a
pleasure and a honor to be with them, and I can say that I
enjoyed every stay very much. I want to express my appreciation
to Prof. John Daly, Chairman of the Department of surgery of
the New York Hospital and thank his hospitality and kindness.

I cannot finish this report without thanking my chief in
Madrid, Prof. E. Moreno-Gonzalez, an example of work and
dedication during all my surgical career.

(Carmelo Loinaz, M.D.)

ISDE News
Editor-in-Chief : Hiroshi Watanabe, M.D. (National Cancer Center)
Member : Nobutoshi Ando, M.D. (Keio University)
            Hiroko Ide, M.D. (Tokyo Women's Medical Coll.)
            Haruhiko Udagawa, M.D. (Toranomon Hospital)
            Koushibe Yoshinari, M.D. (Tokyo Med. & Den. Univ.)
Adviser : J. P. Barro (Tokyo Medical College)
Secretariat : Kenji Ito
               Keiko Tashiro
VI. CONGRESS NEWS

1996
* O. E. S. O. 5th World Congress *
- 5TH POLYDISCIPLINARY WORLD CONGRESS -
  The Esophagogastric Junction
Date : September 3 - 7, 1996
Scientific Director : Robert GIULI
* MEDITERRANEAN CONGRESS OF STAPLING IN SURGERY*
Site : Triacena Congress, Cyprus
Date : November 20 - 24, 1996
President : GAVRIEL KAOZANTIS
* XXX BIENNIAL WORLD CONGRESS OF ICS *
  INTERNATIONAL COLLEGE OF SURGEONS
Site : Kyoto International Hall, Kyoto
Date : November 25 - 29, 1996
Congress President : Osahiko Abe

1997
* 57TH SIC *
International Surgical Week ISW'97:
Site : Acapulco, Mexico
Date : August 24 - 30, 1997
Organizer : E. Moreno-Gonzalez

1998
* 6TH WORLD CONGRESS OF ENDOSCOPIC SURGERY *
Site : Rome, Italy
Date : June 3 - 6, 1998
President : Alberto Montori
* 8TH WORLD CONGRESS OF I.S.D.E.*
Site : Montreal, Canada
Date : September 1 - 4, 1998
Congress Chairman : Andre Duranceau

2001
* 7TH WORLD CONGRESS OF I.S.D.E.*
Site : Sao Paulo, Brazil
Date : 2001
Congress Chairman : H. W. Pinotti

SUPPORTING COMPANIES
* ミノファーゲン製薬本部
* KUREHA CHEMICAL INDUSTRY CO., LTD.
  兵谷化学工業（株）
* 三井製薬工業（株）
* OTSUKA PHARMACEUTICAL CO., LTD.
  大塚製薬（株）
* ヤンソン協和（株）
* CHUUGAI PHARMACEUTICAL CO., LTD.
* TAIHO PHARMACEUTICAL CO., LTD.
  大鵬製品工業（株）
* YAMANOUCHI PHARMACEUTICAL CO., LTD.
  山之内製薬（株）
* スミスクライエンス ビーチャム（株）
* 住友製薬（株）
* SHIONOGI & CO., LTD.
  坂野義製薬（株）
* 木下製薬（株）
* SHIYAMA & CO., LTD.
  八木山製薬（株）
* BANYU PHARMACEUTICAL CO., LTD.
  万有製薬（株）
* 住友ペーパーライト（株）
* KYOWA HAKKO KOGYO CO., LTD.
  協和製薬工業（株）
* 日本化薬
* TERUMO CORPORATION
  テルモジャパン（株）
* 宇治メディカル（株）
* 地化製薬（株）
* NIKKEN CHEMICALS CO., LTD.
  日研化学（株）
* 東京統合化学（株）
* エーザイ（株）
* ヘキストジャパン（株）
* プリストルマイヤーズ
* TSUMURA & CO.
  （株）フムフム

CALL FOR APPLICANTS OF 1997
ISDE SCHOLARSHIP

CONTENTS NO.20 JULY 1ST, 1996
I. 7th World Congress (P.1)
TOWARD FURTHER EXPANSION
THE 7TH WORLD CONGRESS
CELEBRATING
- 20 YEARS -
OF THE ISDE
II. Recent Organizational Development(P.2)
  The 15th Executive Committee Meeting
  May 26, 1995, in Madrid, Spain
  1996 ISDE Scholarship Recipients
III. Regional Activity (P.3)
  *Activity in USA (by F. Henry Ellis, Jr.)*
IV. Scholarship Reports(P.4-6)
  *Reports I. (by Hauhirio Inoue, Japan)*
  *Reports II. (by Paul De Leyn, Belgium)*
  *Reports III. (by Carmelo Loinaz, Spain)*
V. Congress News (P.7)